XTLB
Income statement / Annual
Last year (2024), XTL Biopharmaceuticals Ltd.'s total revenue was $451,000.00,
and the percentage change from the previous year is not available.
In 2024, XTL Biopharmaceuticals Ltd.'s net income was -$1.03 M.
See XTL Biopharmaceuticals Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$451,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$448,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$3,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.01
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$98,000.00
|
$31,000.00
|
$30,000.00
|
$30,000.00
|
$38,000.00
|
$35,000.00
|
$38,000.00
|
$43,000.00
|
$443,000.00
|
$578,000.00
|
| General & Administrative Expenses |
$1.87 M
|
$734,000.00
|
$850,000.00
|
$1.00 M
|
$910,000.00
|
$807,000.00
|
$755,000.00
|
$1.19 M
|
$1.26 M
|
$1.41 M
|
| Selling & Marketing Expenses |
$178,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.05 M
|
$734,000.00
|
$850,000.00
|
$1.00 M
|
$910,000.00
|
$807,000.00
|
$755,000.00
|
$1.19 M
|
$1.26 M
|
$1.41 M
|
| Other Expenses |
$31,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$2.18 M
|
$765,000.00
|
$880,000.00
|
$1.03 M
|
$948,000.00
|
$842,000.00
|
$793,000.00
|
$1.25 M
|
$1.71 M
|
$2.00 M
|
| Cost And Expenses |
$2.62 M
|
$765,000.00
|
$880,000.00
|
$1.03 M
|
$948,000.00
|
$842,000.00
|
$793,000.00
|
$1.25 M
|
$1.71 M
|
$2.00 M
|
| Interest Income |
$34,000.00
|
$36.00
|
$36,000.00
|
$8,000.00
|
$33,000.00
|
$93,000.00
|
$87,000.00
|
$16,000.00
|
$0.00
|
$0.00
|
| Interest Expense |
$28,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$29,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$199,000.00
|
$1,000.00
|
$1,000.00
|
$1,000.00
|
$1,000.00
|
$842,000.00
|
$1,000.00
|
$1,000.00
|
$3,000.00
|
$7,000.00
|
| EBITDA |
-$930,000.00 |
-$764,000.00 |
-$879,000.00 |
-$1.03 M |
-$947,000.00 |
$0.00 |
-$792,000.00 |
-$1.25 M |
-$1.71 M |
-$2.00 M |
| EBITDA Ratio |
-2.06
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-4.82
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.02 M
|
-$1.02 M
|
-$468,000.00
|
$1.47 M
|
-$2.01 M
|
$79,000.00
|
$4.42 M
|
$465,000.00
|
$16,000.00
|
-$11,000.00
|
| Income Before Tax |
-$1.16 M
|
-$1.78 M
|
-$1.35 M
|
$435,000.00
|
-$2.95 M
|
-$1.35 M
|
$2.99 M
|
-$781,000.00
|
-$2.55 M
|
-$3.62 M
|
| Income Before Tax Ratio |
-2.57
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$130,000.00
|
$0.00
|
$468,000.00
|
-$1.47 M
|
$0.00
|
-$69,000.00
|
-$80,000.00
|
-$457,000.00
|
$832,000.00
|
$2.31 M
|
| Net Income |
-$1.03 M
|
-$1,782.00
|
-$1.35 M
|
$435,000.00
|
-$782,000.00
|
-$1.35 M
|
$2.99 M
|
-$781,000.00
|
-$2.55 M
|
-$4.31 M
|
| Net Income Ratio |
-2.28
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.15 |
0 |
-0.25 |
0.1 |
-0.15 |
-0.26 |
0.58 |
-0.17 |
-0.93 |
-1.63 |
| EPS Diluted |
-0.15 |
0 |
-0.25 |
0.07 |
-0.15 |
-0.26 |
0.58 |
-0.17 |
-0.93 |
-1.63 |
| Weighted Average Shares Out |
$6.73 M
|
$5.45 M
|
$5.45 M
|
$5.32 M
|
$5.14 M
|
$5.14 M
|
$5.14 M
|
$4.70 M
|
$2.74 M
|
$2.64 M
|
| Weighted Average Shares Out Diluted |
$7.04 M
|
$5.45 M
|
$5.45 M
|
$6.16 M
|
$5.14 M
|
$5.14 M
|
$5.14 M
|
$4.70 M
|
$2.74 M
|
$2.64 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
